Skip to main content
Erschienen in: Journal of Gastroenterology 12/2018

12.06.2018 | Original Article—Alimentary Tract

A case–control study of the risk of upper gastrointestinal mucosal injuries in patients prescribed concurrent NSAIDs and antithrombotic drugs based on data from the Japanese national claims database of 13 million accumulated patients

verfasst von: Nobuyuki Sugisaki, Ryuichi Iwakiri, Nanae Tsuruoka, Yasuhisa Sakata, Ryo Shimoda, Shun Fujimoto, Yuichiro Eguchi, Kazuma Fujimoto

Erschienen in: Journal of Gastroenterology | Ausgabe 12/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

We aimed to identify the adverse effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and antithrombotics on the upper gastrointestinal (GI) mucosa in a clinical setting as a case–control study using a large-scale medical database in Japan.

Methods

We evaluated the risk of upper GI mucosal injuries in patients receiving NSAIDs and antithrombotics using the Japan Medical Data Center claims database with data for 13 million accumulated patients, from January 2009 to December 2014. Endoscopically evaluated upper GI mucosal injuries were peptic ulcers (n = 143,271), upper GI bleeding (n = 10,545), and gastroesophageal reflux disease (n = 154,755). For each patient, ten controls were matched by age, sex, and diagnosis month.

Results

The odds ratio (OR) for peptic ulcers was 1.45, 1.31, 1.50, 1.53, and 1.62; for upper GI bleeding: 1.76, 1.62, 1.96, 1.82, and 2.38; and for gastroesophageal reflux disease: 1.54, 1.41, 1.89, 1.67, and 1.91 for NSAIDs, COX-2 selective inhibitors, low-dose aspirin, antiplatelet drugs, and anticoagulants, respectively (all statistically significant: P < 0.001). Polypharmacy with NSAIDs and antithrombotic drugs increased the risk of upper GI injuries compared with single-drug therapy. The injury risk was also increased by lifestyle-related diseases, including diabetes mellitus and hyperlipidemia.

Conclusions

This case–control study using the large organized Japanese claims database provided the risk of upper GI mucosal injuries in patients receiving NSAIDs and antithrombotic drugs.
Literatur
1.
Zurück zum Zitat Fujishiro M, Iguchi M, Kakushima N, et al. Guidelines for endoscopic management of non-variceal upper gastrointestinal bleeding. Dig Endosc. 2016;28:363–78.CrossRef Fujishiro M, Iguchi M, Kakushima N, et al. Guidelines for endoscopic management of non-variceal upper gastrointestinal bleeding. Dig Endosc. 2016;28:363–78.CrossRef
2.
Zurück zum Zitat Satoh K, Yoshino J, Akamatsu T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2015. J Gastroenterol. 2016;51:177–94.CrossRef Satoh K, Yoshino J, Akamatsu T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2015. J Gastroenterol. 2016;51:177–94.CrossRef
3.
Zurück zum Zitat Ootani H, Iwakiri R, Shimoda R, et al. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drug use in bleeding peptic ulcers in Japan. J Gastroenterol. 2006;41:41–6.CrossRef Ootani H, Iwakiri R, Shimoda R, et al. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drug use in bleeding peptic ulcers in Japan. J Gastroenterol. 2006;41:41–6.CrossRef
4.
Zurück zum Zitat Sogabe M, Okahisa T, Kimura T, et al. Influence of metabolic syndrome on upper gastrointestinal disease. Clin J Gastroenterol. 2016;9:191–202.CrossRef Sogabe M, Okahisa T, Kimura T, et al. Influence of metabolic syndrome on upper gastrointestinal disease. Clin J Gastroenterol. 2016;9:191–202.CrossRef
5.
Zurück zum Zitat Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl. 1999;56:18–24.PubMed Singh G, Triadafilopoulos G. Epidemiology of NSAID induced gastrointestinal complications. J Rheumatol Suppl. 1999;56:18–24.PubMed
6.
Zurück zum Zitat Matsuura S, Sakata Y, Tsuruoka N, et al. Outcomes of patients undergoing endoscopic hemostasis for the upper gastrointestinal bleeding were not influenced by the timing of hospital emergency visits: a situation prevailing in Japan. Digestion. 2018;97:260–6.CrossRef Matsuura S, Sakata Y, Tsuruoka N, et al. Outcomes of patients undergoing endoscopic hemostasis for the upper gastrointestinal bleeding were not influenced by the timing of hospital emergency visits: a situation prevailing in Japan. Digestion. 2018;97:260–6.CrossRef
7.
Zurück zum Zitat Yamaguchi D, Sakata Y, Yoshida H, et al. Effectiveness of endoscopic hemostasis with soft coagulation for non-variceal upper gastrointestinal bleeding over a 12-year period. Digestion. 2017;95:319–26.CrossRef Yamaguchi D, Sakata Y, Yoshida H, et al. Effectiveness of endoscopic hemostasis with soft coagulation for non-variceal upper gastrointestinal bleeding over a 12-year period. Digestion. 2017;95:319–26.CrossRef
8.
Zurück zum Zitat Buttgereit F, Burmester GR, Simon LS. Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. Am J Med. 2001;110(Suppl 3A):13S–9S.CrossRef Buttgereit F, Burmester GR, Simon LS. Gastrointestinal toxic side effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. Am J Med. 2001;110(Suppl 3A):13S–9S.CrossRef
9.
Zurück zum Zitat Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;4:CD002296. Rostom A, Dube C, Wells G, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev. 2002;4:CD002296.
10.
Zurück zum Zitat Yamaguchi D, Sakata Y, Tsuruoka N, et al. Upper gastrointestinal bleeding in Japanese patients prescribed antithrombotic drugs: differences in trends over time. Hepatogastroenterology. 2014;61:1055–62.PubMed Yamaguchi D, Sakata Y, Tsuruoka N, et al. Upper gastrointestinal bleeding in Japanese patients prescribed antithrombotic drugs: differences in trends over time. Hepatogastroenterology. 2014;61:1055–62.PubMed
11.
Zurück zum Zitat Yamaguchi D, Sakata Y, Tsuruoka N, et al. Characteristics of patients with non-variceal upper gastrointestinal bleeding taking antithrombotic agents. Dig Endosc. 2015;27:30–6.CrossRef Yamaguchi D, Sakata Y, Tsuruoka N, et al. Characteristics of patients with non-variceal upper gastrointestinal bleeding taking antithrombotic agents. Dig Endosc. 2015;27:30–6.CrossRef
12.
Zurück zum Zitat Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160:2093–9.CrossRef Hernández-Díaz S, Rodríguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med. 2000;160:2093–9.CrossRef
13.
Zurück zum Zitat Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55:1731–8.CrossRef Lanas A, García-Rodríguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut. 2006;55:1731–8.CrossRef
14.
Zurück zum Zitat Sakamoto C, Sugano K, Ota S, et al. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol. 2006;62:765–72.CrossRef Sakamoto C, Sugano K, Ota S, et al. Case-control study on the association of upper gastrointestinal bleeding and nonsteroidal anti-inflammatory drugs in Japan. Eur J Clin Pharmacol. 2006;62:765–72.CrossRef
15.
Zurück zum Zitat Nagata N, Niikura R, Sekine K, et al. Risk of peptic ulcer bleeding associated with Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs, low-dose aspirin, and antihypertensive drugs: a case–control study. J Gastroenterol Hepatol. 2015;30:292–8.CrossRef Nagata N, Niikura R, Sekine K, et al. Risk of peptic ulcer bleeding associated with Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs, low-dose aspirin, and antihypertensive drugs: a case–control study. J Gastroenterol Hepatol. 2015;30:292–8.CrossRef
16.
Zurück zum Zitat Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22:795–801.CrossRef Yeomans ND, Lanas AI, Talley NJ, et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther. 2005;22:795–801.CrossRef
17.
Zurück zum Zitat Nema H, Kato M, Katsurada T, et al. Endoscopic survey of low-dose-aspirin induced gastroduodenal mucosal injuries in patients with ischemic heart disease. J Gastroenterol Hepatol. 2008;23:S234–6.CrossRef Nema H, Kato M, Katsurada T, et al. Endoscopic survey of low-dose-aspirin induced gastroduodenal mucosal injuries in patients with ischemic heart disease. J Gastroenterol Hepatol. 2008;23:S234–6.CrossRef
18.
Zurück zum Zitat Uemura N, Sugano K, Hiraishi H, et al. Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study. J Gastroenterol. 2014;49:814–24.CrossRef Uemura N, Sugano K, Hiraishi H, et al. Risk factor profiles, drug usage, and prevalence of aspirin-associated gastroduodenal injuries among high-risk cardiovascular Japanese patients: the results from the MAGIC study. J Gastroenterol. 2014;49:814–24.CrossRef
19.
Zurück zum Zitat Derry S, Loke YK. Risk of gastrointestinal hemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321:1183–7.CrossRef Derry S, Loke YK. Risk of gastrointestinal hemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321:1183–7.CrossRef
20.
Zurück zum Zitat Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162:2197–202.CrossRef Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162:2197–202.CrossRef
21.
Zurück zum Zitat Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000;343:834–9.CrossRef Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med. 2000;343:834–9.CrossRef
22.
Zurück zum Zitat Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case–control study. BMJ. 2006;333:726–8.CrossRef Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case–control study. BMJ. 2006;333:726–8.CrossRef
23.
Zurück zum Zitat Ibáñez L, Vidal X, Vendrell L, et al. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther. 2006;23:235–42.CrossRef Ibáñez L, Vidal X, Vendrell L, et al. Upper gastrointestinal bleeding associated with antiplatelet drugs. Aliment Pharmacol Ther. 2006;23:235–42.CrossRef
24.
Zurück zum Zitat Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ. 2007;177:347–51.CrossRef Delaney JA, Opatrny L, Brophy JM, Suissa S. Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. CMAJ. 2007;177:347–51.CrossRef
25.
Zurück zum Zitat Fujimoto K, Fujishiro M, Kato M, et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc. 2014;26:1–14.CrossRef Fujimoto K, Fujishiro M, Kato M, et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Dig Endosc. 2014;26:1–14.CrossRef
26.
Zurück zum Zitat Chan FKL, Goh K-L, Reddy N, et al. Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guideline. Gut. 2018;67:405–17.CrossRef Chan FKL, Goh K-L, Reddy N, et al. Management of patients on antithrombotic agents undergoing emergency and elective endoscopy: joint Asian Pacific Association of Gastroenterology (APAGE) and Asian Pacific Society for Digestive Endoscopy (APSDE) practice guideline. Gut. 2018;67:405–17.CrossRef
27.
Zurück zum Zitat Lanas Á, Carrera-Lasfuentes P, Arguedas Y, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 2015;13:906–12.CrossRef Lanas Á, Carrera-Lasfuentes P, Arguedas Y, et al. Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 2015;13:906–12.CrossRef
28.
Zurück zum Zitat Coleman CI, Sobieraj DM, Winkler S, et al. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Pract. 2012;66:53–63.CrossRef Coleman CI, Sobieraj DM, Winkler S, et al. Effect of pharmacological therapies for stroke prevention on major gastrointestinal bleeding in patients with atrial fibrillation. Int J Clin Pract. 2012;66:53–63.CrossRef
29.
Zurück zum Zitat Miller CS, Dorreen A, Martel M, et al. Risk of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15:1674–83.CrossRef Miller CS, Dorreen A, Martel M, et al. Risk of gastrointestinal bleeding in patients taking non-vitamin K antagonist oral anticoagulants: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2017;15:1674–83.CrossRef
30.
Zurück zum Zitat Heublein V, Pannach S, Daschoknow K, et al. Gastrointestinal endoscopy in patients receiving novel direct anticoagulants: results from the prospective Dresden NOAC registry. J Gastroenterol. 2018;53:236–46.CrossRef Heublein V, Pannach S, Daschoknow K, et al. Gastrointestinal endoscopy in patients receiving novel direct anticoagulants: results from the prospective Dresden NOAC registry. J Gastroenterol. 2018;53:236–46.CrossRef
31.
Zurück zum Zitat Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103:2465–73.CrossRef Yeomans N, Lanas A, Labenz J, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol. 2008;103:2465–73.CrossRef
32.
Zurück zum Zitat Sugimoto M, Uotani T, Ichikawa H, et al. Gastroesophageal reflux disease in time covering eradication for all patients infected with Helicobacter pylori in Japan. Digestion. 2016;93:24–31.CrossRef Sugimoto M, Uotani T, Ichikawa H, et al. Gastroesophageal reflux disease in time covering eradication for all patients infected with Helicobacter pylori in Japan. Digestion. 2016;93:24–31.CrossRef
33.
Zurück zum Zitat Sanuki T, Fujita T, Kutsumi H, et al. Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial. J Gastroenterol. 2012;47:1186–97.CrossRef Sanuki T, Fujita T, Kutsumi H, et al. Rabeprazole reduces the recurrence risk of peptic ulcers associated with low-dose aspirin in patients with cardiovascular or cerebrovascular disease: a prospective randomized active-controlled trial. J Gastroenterol. 2012;47:1186–97.CrossRef
34.
Zurück zum Zitat Nakayama M, Iwakiri R, Hara M, et al. Low-dose aspirin is a prominent cause of bleeding ulcers in patients who underwent emergency endoscopy. J Gastroenterol. 2009;44:912–8.CrossRef Nakayama M, Iwakiri R, Hara M, et al. Low-dose aspirin is a prominent cause of bleeding ulcers in patients who underwent emergency endoscopy. J Gastroenterol. 2009;44:912–8.CrossRef
35.
Zurück zum Zitat Tsuruoka N, Iwakiri R, Sakata Y, et al. Questionnaire-based survey on gastrointestinal bleeding and management of antithrombotic agents during endoscopy among Asian countries. Digestion. 2018;97:97–106.CrossRef Tsuruoka N, Iwakiri R, Sakata Y, et al. Questionnaire-based survey on gastrointestinal bleeding and management of antithrombotic agents during endoscopy among Asian countries. Digestion. 2018;97:97–106.CrossRef
36.
Zurück zum Zitat Ito Y, Sakata Y, Yoshida H, et al. High cost of hospitalization for colonic diverticular bleeding depended on repeated bleeding and blood transfusion: analysis with diagnosis procedure combination (DPC) data in Japan. Digestion. 2017;96:76–80.CrossRef Ito Y, Sakata Y, Yoshida H, et al. High cost of hospitalization for colonic diverticular bleeding depended on repeated bleeding and blood transfusion: analysis with diagnosis procedure combination (DPC) data in Japan. Digestion. 2017;96:76–80.CrossRef
37.
Zurück zum Zitat Chan FK, Kyaw M, Tanigawa T, et al. Similar efficacy of proton-pump inhibitors vs H2-receptor antagonists in reducing risk of upper gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin. Gastroenterology. 2017;152:105–10.CrossRef Chan FK, Kyaw M, Tanigawa T, et al. Similar efficacy of proton-pump inhibitors vs H2-receptor antagonists in reducing risk of upper gastrointestinal bleeding or ulcers in high-risk users of low-dose aspirin. Gastroenterology. 2017;152:105–10.CrossRef
38.
Zurück zum Zitat Nagata N, Niikura R, Yamada A, et al. Acute middle gastrointestinal bleeding risk associated with NSAIDs, antithrombotic drugs, and PPIs: a multicenter case-control study. PLoS One. 2016;11:e0151332.CrossRef Nagata N, Niikura R, Yamada A, et al. Acute middle gastrointestinal bleeding risk associated with NSAIDs, antithrombotic drugs, and PPIs: a multicenter case-control study. PLoS One. 2016;11:e0151332.CrossRef
39.
Zurück zum Zitat Sener G, Goren FO, Ulusoy NB, et al. Protective effect of melatonin and omeprazole against alendronate-induced gastric damage. Dig Dis Sci. 2005;50:1506–12.CrossRef Sener G, Goren FO, Ulusoy NB, et al. Protective effect of melatonin and omeprazole against alendronate-induced gastric damage. Dig Dis Sci. 2005;50:1506–12.CrossRef
40.
Zurück zum Zitat Nagano Y, Matsui H, Shimokawa O, et al. Biophosphonate-induced gastrointestinal mucosal injury is medicated by mitochondrial superoxide production and lipid peroxidation. J Clin Biochem Nutr. 2012;51:196–203.PubMedPubMedCentral Nagano Y, Matsui H, Shimokawa O, et al. Biophosphonate-induced gastrointestinal mucosal injury is medicated by mitochondrial superoxide production and lipid peroxidation. J Clin Biochem Nutr. 2012;51:196–203.PubMedPubMedCentral
41.
Zurück zum Zitat Zografos GN, Georgiadou D, Thomas D, et al. Drug-induced esophagitis. Dis Esophagus. 2009;22:633–7.CrossRef Zografos GN, Georgiadou D, Thomas D, et al. Drug-induced esophagitis. Dis Esophagus. 2009;22:633–7.CrossRef
42.
Zurück zum Zitat Tseng CL, Chen YT, Huang CJ, et al. Short-term use of glucocorticoids and risk of peptic ulcer bleeding: a nationwide population-based case-crossover study. Aliment Pharmacol Ther. 2015;42:599–606.CrossRef Tseng CL, Chen YT, Huang CJ, et al. Short-term use of glucocorticoids and risk of peptic ulcer bleeding: a nationwide population-based case-crossover study. Aliment Pharmacol Ther. 2015;42:599–606.CrossRef
43.
Zurück zum Zitat Asaoka D, Nagahara A, Hojo M, et al. Association of medications for lifestyle-related diseases with reflux esophagitis. Ther Clin Risk Manag. 2016;12:1507–15.CrossRef Asaoka D, Nagahara A, Hojo M, et al. Association of medications for lifestyle-related diseases with reflux esophagitis. Ther Clin Risk Manag. 2016;12:1507–15.CrossRef
44.
Zurück zum Zitat Rosenstock S, Jørgensen T, Bonnevie O, Andersen L. Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults. Gut. 2003;52:186–93.CrossRef Rosenstock S, Jørgensen T, Bonnevie O, Andersen L. Risk factors for peptic ulcer disease: a population based prospective cohort study comprising 2416 Danish adults. Gut. 2003;52:186–93.CrossRef
45.
Zurück zum Zitat Tanaka S, Seto K, Kawakami K. Pharmacoepidemiology in Japan: medical databases and research achievements. J Pharm Health Care Sci. 2015;1:16.CrossRef Tanaka S, Seto K, Kawakami K. Pharmacoepidemiology in Japan: medical databases and research achievements. J Pharm Health Care Sci. 2015;1:16.CrossRef
46.
Zurück zum Zitat Kimura S, Sato T, Ikeda S, et al. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol. 2010;20:413–9.CrossRef Kimura S, Sato T, Ikeda S, et al. Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol. 2010;20:413–9.CrossRef
47.
Zurück zum Zitat Sakamoto C, Soen S. Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan. Digestion. 2011;83:108–23.CrossRef Sakamoto C, Soen S. Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan. Digestion. 2011;83:108–23.CrossRef
48.
Zurück zum Zitat Sakamoto C, Kawai T, Nakamura S, et al. Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study. Aliment Pharmacol Ther. 2013;37:346–54.CrossRef Sakamoto C, Kawai T, Nakamura S, et al. Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study. Aliment Pharmacol Ther. 2013;37:346–54.CrossRef
49.
Zurück zum Zitat Yamamoto T, Ebato T, Mishina Y, et al. Thienopyridine and cilostazol are safer for gastroduodenal mucosa than low-dose aspirin-second report of endoscopic evaluation. Thromb Res. 2010;125:365–6.CrossRef Yamamoto T, Ebato T, Mishina Y, et al. Thienopyridine and cilostazol are safer for gastroduodenal mucosa than low-dose aspirin-second report of endoscopic evaluation. Thromb Res. 2010;125:365–6.CrossRef
50.
Zurück zum Zitat Tsai TJ, Lai KH, Hsu PI, et al. Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy. J Formos Med Assoc. 2012;111:705–10.CrossRef Tsai TJ, Lai KH, Hsu PI, et al. Upper gastrointestinal lesions in patients receiving clopidogrel anti-platelet therapy. J Formos Med Assoc. 2012;111:705–10.CrossRef
51.
Zurück zum Zitat Wilhite DB, Comerota AJ, Schmieder FA, et al. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg. 2003;38:710–3.CrossRef Wilhite DB, Comerota AJ, Schmieder FA, et al. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg. 2003;38:710–3.CrossRef
52.
Zurück zum Zitat Ma L, Elliott SN, Cirino G, et al. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci USA. 2001;98:6470–5.CrossRef Ma L, Elliott SN, Cirino G, et al. Platelets modulate gastric ulcer healing: role of endostatin and vascular endothelial growth factor release. Proc Natl Acad Sci USA. 2001;98:6470–5.CrossRef
53.
Zurück zum Zitat Cryer B. Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. N Engl J Med. 2005;352:287–9.CrossRef Cryer B. Reducing the risks of gastrointestinal bleeding with antiplatelet therapies. N Engl J Med. 2005;352:287–9.CrossRef
54.
Zurück zum Zitat Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. Risk factors for erosive reflux esophagitis: a case–control study. Am J Gastroenterol. 2001;96:41–6.CrossRef Avidan B, Sonnenberg A, Schnell TG, Sontag SJ. Risk factors for erosive reflux esophagitis: a case–control study. Am J Gastroenterol. 2001;96:41–6.CrossRef
55.
Zurück zum Zitat Sugimoto M, Uotani T, Nishino M, et al. Antiplatelet drugs are a risk factor for esophageal mucosal injury. Digestion. 2013;87:281–9.CrossRef Sugimoto M, Uotani T, Nishino M, et al. Antiplatelet drugs are a risk factor for esophageal mucosal injury. Digestion. 2013;87:281–9.CrossRef
56.
Zurück zum Zitat Toya Y, Nakamura S, Tomita K, et al. Dabigatran-induced esophagitis: the prevalence and endoscopic characteristics. J Gastroenterol Hepatol. 2016;31:610–4.CrossRef Toya Y, Nakamura S, Tomita K, et al. Dabigatran-induced esophagitis: the prevalence and endoscopic characteristics. J Gastroenterol Hepatol. 2016;31:610–4.CrossRef
57.
Zurück zum Zitat García Rodríguez LA. Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis. Semin Arthritis Rheum. 1997;26:16–20.CrossRef García Rodríguez LA. Nonsteroidal antiinflammatory drugs, ulcers and risk: a collaborative meta-analysis. Semin Arthritis Rheum. 1997;26:16–20.CrossRef
58.
Zurück zum Zitat Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363–72.CrossRef Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123:2363–72.CrossRef
59.
Zurück zum Zitat Iwakiri R, Higuchi K, Kato M, et al. Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2014;40:780–95.CrossRef Iwakiri R, Higuchi K, Kato M, et al. Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. Aliment Pharmacol Ther. 2014;40:780–95.CrossRef
60.
Zurück zum Zitat Fujishiro M, Higuchi K, Kato M, et al. Long-term efficacy and safety of rabeprazole in patients taking low-dose aspirin with a history of peptic ulcers: a phase 2/3, randomized, parallel-group, multicenter, extension clinical trial. J Clin Biochem Nutr. 2015;56:228–39.CrossRef Fujishiro M, Higuchi K, Kato M, et al. Long-term efficacy and safety of rabeprazole in patients taking low-dose aspirin with a history of peptic ulcers: a phase 2/3, randomized, parallel-group, multicenter, extension clinical trial. J Clin Biochem Nutr. 2015;56:228–39.CrossRef
61.
Zurück zum Zitat Sugano K, Kontani T, Katsuo S, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2012;47:540–52.CrossRef Sugano K, Kontani T, Katsuo S, et al. Lansoprazole for secondary prevention of gastric or duodenal ulcers associated with long-term non-steroidal anti-inflammatory drug (NSAID) therapy: results of a prospective, multicenter, double-blind, randomized, double-dummy, active-controlled trial. J Gastroenterol. 2012;47:540–52.CrossRef
62.
Zurück zum Zitat Mizokami Y, Oda K, Funao N, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut. 2018;67:1042–51.CrossRef Mizokami Y, Oda K, Funao N, et al. Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study. Gut. 2018;67:1042–51.CrossRef
63.
Zurück zum Zitat Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619–32.CrossRef Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med. 1994;236:619–32.CrossRef
64.
Zurück zum Zitat Lanza FL, Hunt RH, Thomson AB, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology. 2000;119:631–8.CrossRef Lanza FL, Hunt RH, Thomson AB, et al. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology. 2000;119:631–8.CrossRef
65.
Zurück zum Zitat Miyake K, Kusunoki M, Shinji Y, et al. Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy. J Gastroenterol. 2009;44:113–20.CrossRef Miyake K, Kusunoki M, Shinji Y, et al. Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy. J Gastroenterol. 2009;44:113–20.CrossRef
66.
Zurück zum Zitat Mizuno T, Shindo K. Acute gastric ulceration due to excessive reduction of blood pressure in hypertensive patients. Jpn J Med. 1989;28:269–71.CrossRef Mizuno T, Shindo K. Acute gastric ulceration due to excessive reduction of blood pressure in hypertensive patients. Jpn J Med. 1989;28:269–71.CrossRef
67.
Zurück zum Zitat Peng YL, Leu HB, Luo JC, et al. Diabetes is an independent risk factor for peptic ulcer bleeding: a nationwide population-based cohort study. J Gastroenterol Hepatol. 2013;28:1295–9.CrossRef Peng YL, Leu HB, Luo JC, et al. Diabetes is an independent risk factor for peptic ulcer bleeding: a nationwide population-based cohort study. J Gastroenterol Hepatol. 2013;28:1295–9.CrossRef
68.
Zurück zum Zitat Chen T, Lu M, Wang X, et al. Prevalence and risk factors of gastroesophageal reflux symptoms in a Chinese retiree cohort. BMC Gastroenterol. 2012;12:161.CrossRef Chen T, Lu M, Wang X, et al. Prevalence and risk factors of gastroesophageal reflux symptoms in a Chinese retiree cohort. BMC Gastroenterol. 2012;12:161.CrossRef
69.
Zurück zum Zitat Moki F, Kusano M, Mizuide M, et al. Association between reflux oesophagitis and features of the metabolic syndrome in Japan. Aliment Pharmacol Ther. 2007;26:1069–75.CrossRef Moki F, Kusano M, Mizuide M, et al. Association between reflux oesophagitis and features of the metabolic syndrome in Japan. Aliment Pharmacol Ther. 2007;26:1069–75.CrossRef
70.
Zurück zum Zitat Udd M, Miettinen P, Palmu A, et al. Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: a case-control study. Scand J Gastroenterol. 2007;42:1395–403.CrossRef Udd M, Miettinen P, Palmu A, et al. Analysis of the risk factors and their combinations in acute gastroduodenal ulcer bleeding: a case-control study. Scand J Gastroenterol. 2007;42:1395–403.CrossRef
Metadaten
Titel
A case–control study of the risk of upper gastrointestinal mucosal injuries in patients prescribed concurrent NSAIDs and antithrombotic drugs based on data from the Japanese national claims database of 13 million accumulated patients
verfasst von
Nobuyuki Sugisaki
Ryuichi Iwakiri
Nanae Tsuruoka
Yasuhisa Sakata
Ryo Shimoda
Shun Fujimoto
Yuichiro Eguchi
Kazuma Fujimoto
Publikationsdatum
12.06.2018
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 12/2018
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-018-1483-x

Weitere Artikel der Ausgabe 12/2018

Journal of Gastroenterology 12/2018 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.